Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1986 Sep;23(1):73–77. doi: 10.1007/BF00205559

The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice

Hideki Ozawa 1,, Takao Iwaguchi 1, Tateshi Kataoka 2
PMCID: PMC11037942  PMID: 3533258

Abstract

Spleen cells of BALB/c mice hyperimmunized with a transplantable methylcholanthrene-induced sarcoma Meth A (Meth A-Im-SPL) inhibited the growth of Meth A tumor in vivo in a tumor neutralizing test. Meth A-Im-SPL did not neutralize another antienically distinct sarcoma, Meth 1, indicating that the antitumor activity is tumor specific. Lyt-1+2 cells of Meth A-Im-SPL (Im-Lyt-1+2) were the effectors since in vitro treatment of Meth A-Im-SPL with anti-Thy 1.2 or anti-Lyt 1.2 antibody plus complement completely abrogated their neutralizing activity, whereas treatment with anti-Lyt 2.2 plus complement did not. To further confirm the effector activity of Im-Lyt-1+2 cells, T cell subpopulations were separated from Meth A-Im-SPL by the panning method. The purified Im-Lyt-1+2, but not Im-Lyt-1+2+ cells neutralized the tumor in athymic nu/nu mice as efficiently as in +/+ mice, suggesting that the donor Im-Lyt-1+2 cells but not recipient T cells were primarily responsible for neutralizing the tumor. The present study, however, did not exclude the possible contribution of recipient T cells to the tumor neutralization and this is open to further investigation.

Keywords: Cancer Research, Sarcoma, Antitumor Activity, Spleen Cell, Effector Activity

Abbreviations

Meth A-Im-SPL

Meth A-immune mouse spleen cells

Meth 1-Im-SPL

Meth 1-immune mouse spleen cells

sIg+ cells

surface immunoglobulin positive cells

moAb

monoclonal antibody

References

  • 1.Ando I, Hurme M. Self-MHC-restricted cytotoxic T-cell responce without thymic influence. Nature. 1981;289:494. doi: 10.1038/289494a0. [DOI] [PubMed] [Google Scholar]
  • 2.Gillis S, Watson J. Interleukin-2 induction of hapten-specific cytotoxic T cells in nude mice. J Immunol. 1981;126:1245. [PubMed] [Google Scholar]
  • 3.Gillis S, Union NA, Baker PE, Smith KA. The in vitro generation and sustained culture of nude mouse cytotoxic T-lymphocytes. J Exp Med. 1979;149:1460. doi: 10.1084/jem.149.6.1460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Huber B, Cantor H, Shen FW, Boyse EA. Independent differentiative pathways of Ly1 and Ly23 subclasses of T cells: Experimental production of mice deprived of selected T-cell subclasses. J Exp Med. 1976;144:1128. doi: 10.1084/jem.144.4.1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hunig T, Bevan MJ. Specificity of cytotoxic T cells from athymic mice. J Exp Med. 1980;152:688. doi: 10.1084/jem.152.3.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kataoka T, Oh-Hashi F, Akabori Y, Sakurai Y, Okabe M, Gomi K. Tumor dependency of concanavalin A-induced potentiation of tumor cell immunogenecity. Gann. 1983;74:412. [PubMed] [Google Scholar]
  • 7.Mage MG, McHuch LL, Rothstein TL. Mouse lymphocytes with and without surface immunoglobulin: Preparative scale separation in polystyrene tissue culture dishes coated with specifically purified anti-immunoglobulin. J Immunol Methods. 1977;15:47. doi: 10.1016/0022-1759(77)90016-3. [DOI] [PubMed] [Google Scholar]
  • 8.Nelson M, Nelson DS, McKenzie IFC, Blanden RV. Thy and Ly markers on lymphocytes initiating tumor rejection. Cell Immunol. 1981;60:34. doi: 10.1016/0008-8749(81)90245-8. [DOI] [PubMed] [Google Scholar]
  • 9.North RJ, Bursuker I. Generation and decay of the immune responce to a progressive fibrosarcoma: I. Ly-+2− suppressor T cells down-regulate the generation of Ly-1−2+ effector T cells. J Exp Med. 1984;159:1295. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Old LJ, Boyse EA, Clarke DA, Carswell EA. Antigenic properties of chemically induced tumors. Ann NY Acad Sci. 1962;101:80. [Google Scholar]
  • 11.Perry LL, Greene MI. T cell subset interactions in the regulation of syngeneic tumor immunity. Fed Proc. 1981;40:39. [PubMed] [Google Scholar]
  • 12.Prat M, Di Renzo BF, Comoglio PM. Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. Int J Cancer. 1983;31:757. doi: 10.1002/ijc.2910310614. [DOI] [PubMed] [Google Scholar]
  • 13.Rollinghoff M, Warner NL. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells. Proc Soc Exp Biol Med. 1973;144:813. doi: 10.3181/00379727-144-37688. [DOI] [PubMed] [Google Scholar]
  • 14.Rosenstein M, Eberlein TJ, Rosenberg SA. Adoptive immunotherapy of established syngeneic solid tumors. J Immunol. 1984;132:2117. [PubMed] [Google Scholar]
  • 15.Shimizu K, Shen FW. Role of different T cell sets in the rejection of chemically induced tumors. J Immunol. 1979;122:1162. [PubMed] [Google Scholar]
  • 16.Wagner H, Hardt C, Heeg K, Rollinghoff M, Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature. 1980;284:278. doi: 10.1038/284278a0. [DOI] [PubMed] [Google Scholar]
  • 17.Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol. 1961;86:228. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES